Investor excitement following encouraging clinical trial findings was reflected in the substantial increase in the stock price of Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) on Thursday. During regular trading, CELZ shares rose 11.14%, concluding at $4.59. After-hours trading saw an additional 8.93% increase, hitting $5.00.
Promising Results for Type 2 Diabetes Therapy
Creative Medical Technology released one-year follow-up data from its AlloStem (CELZ-201) pilot study, targeting late-stage Type 2 Diabetes patients. CELZ-201 is an allogenic, ready-to-use cell therapy designed to reduce insulin dependency and stabilize blood sugar levels. The study demonstrated an 80% overall efficacy rate in achieving these outcomes, with no reported serious adverse effects.
The trial involved 20 participants, with 10 receiving the CELZ-201 infusion and 10 undergoing optimized medical therapy. Results confirmed the safety and effectiveness of the treatment, which utilizes the same infusion method currently being tested in the company’s FDA-approved Type 1 Diabetes clinical trial. The lack of safety issues emphasizes even more how promising CELZ-201 is as a ground-breaking diabetic therapy.
Resolving a Pervasive Health Issue
Type 2 diabetes, the seventh greatest cause of death in the US, affects 90–95% of the 38 million Americans and is a serious public health risk. More than 80% of the 96 million people who have prediabetes are not aware that they have the disease. Even though early-stage management involves lifestyle changes and oral medications, many patients eventually require insulin treatment as the diabetes worsens.
Future Growth and Innovation
In light of these encouraging outcomes, Creative Medical Technology plans to investigate other therapeutic uses and expedite the development of AlloStem or CELZ-201 for advanced Type 2 Diabetes. The company’s diverse pipeline, which includes CELZ-201 for Type 1 diabetes in its early stages and CELZ-101 for brittle Type 1 diabetes, demonstrates its dedication to developing cutting-edge therapies that might fundamentally alter the way diabetes is managed.